Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
To determine the antitumor activity, based on the confirmed objective response rate, of KOS-862, administered intravenously weekly for 3 weeks every 4 weeks, in patients with non-small cell lung cancer (NSCLC) whose disease has progressed following initial chemotherapy for advanced or metastatic disease.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
At least 18 years of age
Measurable disease
One previous treatment of a platinum based drug such as cisplatin or carboplatin
At least 3 weeks since last surgery/radiation/chemotherapy
You may not be if
Brain metastases
Changes in the rhythm of your heart that are considered significant as determined by an ECG tracing